Company intelligence / Profile preview
Targeted Genetics Corporation
Seattle, Washington, United Statestargetedgenetics.com ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Other
01
Overview
Targeted Genetics developed AAV-based gene therapies targeting ocular and neurological diseases. Its lead program was an AAV-RPE65 candidate for LCA/severe retinal dystrophies, which reached clinical stage. Other programs included preclinical candidates for Huntington’s disease and ALS. The company struggled financially, sold key manufacturing assets to Genzyme in 2009, and ceased active development shortly thereafter.
- Therapeutic areas
- RheumatologyOphthalmologyNeurologyInfectious Diseases
- Modalities
- Gene therapyRNA interferenceRetroviral vectors
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Celladon CorporationAmsterdam Molecular TherapeuticsFred Hutchinson Cancer Research Center
Beyond the preview
Go deeper on Targeted Genetics Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Targeted Genetics Corporation.